|Awarded On||May 18, 2016|
|Title||Defining and Defeating Mechanistic Subtypes of KRAS-mutant Lung Cancers|
|Award Mechanism||Multi-Investigator Research Awards (Version 2)|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Jonathan M Kurie|
|Cancer Sites||Lung and Bronchus|
Lung cancer is the primary cause of cancer-related death worldwide. Underlying this problem, conventional chemotherapies and radiation therapy are frequently ineffective once lung cancer has spread from the lung to other parts of the body in a process called metastasis. Newer therapies have begun to make inroads into this problem based on the discovery that lung cancer cells become “addicted” to alterations (“mutations”) in genes that cause a normal lung cell to become a cancer cell. For example, mutations in genes called EGFR and ALK found in lung cancer dramatically respond to erlotinib and crizotinib, drugs that directly target EGFR and ALK, respectively, and prolong survival in lung canc...